Leukemia, Lymphoma, Myeloma Cancer News |Hematologic & Blood

Hematologic Cancers News


Hematologic Cancers News

Biosimilar Riabni Gets FDA Approval

The biosimilar has been approved for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.

Xpovio Multiple Myeloma Indication Expanded

The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
Next post in Chronic Lymphocytic Leukemia